DNA methyltransferase inhibitors are widely used in preclinical and clinical studies, but poor pharmacokinetics and low efficacy in solid tumors limit their therapeutic use. A new study reports the development and characterization of a specific, non-covalent DNA methyltransferase inhibitor with more-durable DNA hypomethylation and lower toxicity than that of nucleoside analogs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer
Translational Medicine Communications Open Access 19 January 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jones, P. A. & Liang, G. Nat. Rev. Genet. 10, 805–811 (2009).
Roulois, D. et al. Cell 162, 961–973 (2015).
Chiappinelli, K. B. et al. Cell 162, 974–986 (2015).
Pappalardi, M. B. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00249-x (2021).
Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Nature 429, 457–463 (2004).
Mehdipour, P., Murphy, T. & De Carvalho, D. D. Pharmacol. Ther. 205, 107416 (2020).
Mehdipour, P. et al. Nature 588, 169–173 (2020).
Loo Yau, H. et al. Mol. Cell 81, 1469–1483.e8 (2021).
Fresquet, V. et al. Cancer Discov. 11, 1268–1285 (2021).
Derissen, E. J. B., Beijnen, J. H. & Schellens, J. H. M. Oncologist 18, 619–624 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.D.D.C. received research funds from Pfizer and Nektar Therapeutics, and is co-founder and chief scientific officer at Adela.
Rights and permissions
About this article
Cite this article
Mehdipour, P., Chen, R. & De Carvalho, D.D. The next generation of DNMT inhibitors. Nat Cancer 2, 1000–1001 (2021). https://doi.org/10.1038/s43018-021-00271-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00271-z
This article is cited by
-
iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer
Translational Medicine Communications (2024)
-
Regulatory mechanism and biological function of UHRF1–DNMT1-mediated DNA methylation
Functional & Integrative Genomics (2022)